8-K filing — GYRE THERAPEUTICS, INC. (GYRE)
Filed: 2026-08-26 AccNo: 0001140361-26-034401 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
8-K filing — GYRE THERAPEUTICS, INC. (GYRE)
Filed: 2026-08-07 AccNo: 0001193125-26-339223 Size: 722 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 7, 2026, 12:00 PM
- Checked
- Aug 7, 2026, 12:00 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M Est
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $102.300 million estimate.
Read original at benzingaGyre Therapeutics Q2 EPS $(0.12) Misses $(0.04) Estimate, Sales $29.105M Beat $26.490M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.04) by 200 percent. The company reported quarterly sales of $29.105 million which beat
Read original at benzinga8-K/A filing — GYRE THERAPEUTICS, INC. (GYRE)
Filed: 2026-07-15 AccNo: 0001140361-26-028564 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar